Reimundo Pilar, Gutiérrez Romero Javier M, Rodríguez Pérez Tamara, Veiga Ernesto
Laboratory of Assisted Reproduction and Andrology, Area of Clinical Biochemistry, Vall d'Hebron Clinical Laboratories, Vall d'Hebron University Hospital, Barcelona, Spain.
Clinical Management Unit of Clinical Laboratories, Puerta del Mar University Hospital, Cadiz, Spain.
Adv Lab Med. 2021 Apr 2;2(2):179-198. doi: 10.1515/almed-2021-0013. eCollection 2021 May.
In the early days of assisted reproductive technology (ART), the main target was achieving gestation. Success rates were low, and multiple embryo transfers became common practice, with multiple pregnancies being 20 times higher than in natural conception. Multiple pregnancy is associated with a higher risk of complications for the mother and the baby than a singleton pregnancy. Added to healthcare costs, multiple pregnancy also involves other costs and psychosocial risks, with a high social and health costs. At present, success rates of assisted human reproduction (AHR) have improved dramatically, partially due to advances in laboratory techniques such as culture of blastocyst-stage embryos and vitrification. Additionally, there is a wide range of counseling, health and economic policies that have demonstrated being effective in increasing single-embryo transfer (SET) practices and reducing multiple pregnancies, which ensures satisfactory success rates. Therefore, single-embryo transfer emerges as the approach of choice for AHR to result in a full-term healthy newborn.
在辅助生殖技术（ART）早期，主要目标是实现妊娠。成功率很低，多胚胎移植成为常见做法，多胎妊娠发生率比自然受孕高20倍。与单胎妊娠相比，多胎妊娠对母亲和婴儿的并发症风险更高。除了医疗成本，多胎妊娠还涉及其他成本和心理社会风险，社会和健康成本高昂。目前，辅助人类生殖（AHR）的成功率已大幅提高，部分原因是实验室技术的进步，如囊胚期胚胎培养和玻璃化。此外，有广泛的咨询、健康和经济政策已证明在增加单胚胎移植（SET）做法和减少多胎妊娠方面有效，这确保了令人满意的成功率。因此，单胚胎移植成为辅助人类生殖实现足月健康新生儿的首选方法。
